BMY - Bristol-Myers Squibb Company

NYSE - NYSE Delayed Price. Currency in USD

Bristol-Myers Squibb Company

345 Park Avenue
New York, NY 10154
United States
212-546-4000
http://www.bms.com

SectorHealthcare
IndustryDrug Manufacturers - Major
Full Time Employees23,700

Key Executives

NameTitlePayExercisedYear Born
Dr. Giovanni CaforioChairman & CEO5.11M3.17M1965
Mr. Charles A. BancroftExec. VP of Global Bus. Operations & CFO2.85MN/A1960
Dr. Thomas J. Lynch Jr.Exec. VP of R&D & Chief Scientific Officer152.5kN/A1961
Ms. Sandra LeungExec. VP & Gen. Counsel2.45M5.17M1961
Mr. Joseph C. CaldarellaSr. VP, Corp. Controller & Principal Accounting OfficerN/AN/A1956
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection. Its products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in atrial fibrillation and the prevention and treatment of venous thromboembolic disorders; Orencia, a biological product that targets adult patients with active rheumatoid arthritis and prostate-specific antigen; and Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. The company's products also comprise Yervoy, a monoclonal antibody for the treatment of adults and pediatric patients with unresectable or metastatic melanoma; Empliciti, a human monoclonal antibody for the treatment of multiple myeloma; Baraclude, a potent and selective inhibitor of the hepatitis B virus; Sustiva, a non-nucleoside reverse transcriptase inhibitor for HIV and bulk efavirenz; Reyataz, a protease inhibitor for the treatment of HIV and combination therapy Evotaz; Daklinza, an oral small molecule NS5A replication complex inhibitor for the treatment of hepatitis C virus (HCV); and Sunvepra, an oral small molecule for the treatment of HCV. It sells products to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. Bristol-Myers Squibb Company has a research partnership with Sirenas; and a collaboration agreement with Nektar Therapeutics, Illumina, Inc., Janssen Pharmaceuticals, Inc., and Advantagene, Inc., as well as Tsinghua University. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

Corporate Governance

Bristol-Myers Squibb Company’s ISS Governance QualityScore as of September 1, 2018 is 4. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 5; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.